Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Subsequently, we assessed the interrelationship between this prognostic signature, the tumor microenvironment, and the gene mutational landscape, while concurrently exploring potential therapeutic candidates capable of exerting favorable effects in OC
Some users prefer copper peptide treatment from a single product, using non-copper-peptide formulations for other skincare steps
Features Customizable shape and emergence profile
Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): phase 3 study results [Abstract]
Synonyms: Gly-His-Lys-Cu(II)
User Level
US$ 24.99
US$ 20.56
US$ 20.63
US$ 27.36
US$ 29.51
